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Context: Adipose tissue is a highly active endocrine organ that secretes many factors that affect
other tissues and whole-body metabolism. Adipocytes are responsive to several glycoprotein 130
(gp130) cytokines, some of which have been targeted as potential antiobesity therapeutics.
Objective: Oncostatin M (OSM) is a gp130 family member known to inhibit adipocyte differenti-
ation in vitro, but its effects on other adipocyte properties are not characterized. The expression
of OSM in white adipose tissue (WAT) has not been evaluated in the context of obesity. Thus, our
objective was to examine the expression of adipose tissue OSM in obese animals and humans.
Design: OSM expression was examined in adipose tissues from mice with diet-induced and genetic
obesity and in obese humans as well as in fractionated adipose tissue from mice. Murine adipocytes
were used to examine OSM receptor expression and the effects of OSM on adipocytes, including
the secretion of factors such as plasminogen activator inhibitor 1 and IL-6, which are implicated in
metabolic diseases.
Results: OSM expression is increased in rodent and human obesity/type 2 diabetes mellitus. In
humans, OSM levels correlate with body weight and insulin and are inversely correlated with
glucose disposal rate as measured by hyperinsulinemic-euglycemic clamp. OSM is not produced
from the adipocytes in WAT but derives from cells in the stromovascular fraction, including F4/80
macrophages. The specific receptor of OSM, OSM receptor-, is expressed in adipocytes and adi-
pose tissue and increased in both rodent models of obesity examined. OSM acts on adipocytes to
induce the expression and secretion of plasminogen activator inhibitor 1 and IL-6.
Conclusions: These data indicate that WAT macrophages are a source of OSM and that OSM levels
are significantly induced in murine and human obesity/type 2 diabetes mellitus. These studies
suggest that OSM produced from immune cells in WAT acts in a paracrine manner on adipocytes
to promote a proinflammatory phenotype in adipose tissue. (J Clin Endocrinol Metab 99:
E217–E225, 2014)
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diet; LIF, leukemia inhibitory factor; MCP-1, monocyte chemoattractant protein-1; NP,
neuropoietin; OSM, oncostatin M; OSMR, OSM receptor-; PBRC, Pennington Biomed-
ical Research Center; STAT, signal transducer and activator of transcription; SVF, stromo-
vascular fraction; T2DM, type 2 diabetes mellitus; WAT, white adipose tissue.
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The IL-6 family is a group of functionally and structur-ally related cytokines that include IL-6, IL-11, IL-27,
leukemia inhibitory factor (LIF), oncostatin M (OSM),
ciliary neurotrophic factor, cardiotrophin-1 (CT-1), novel
neurotrophin-1/B cell stimulating factor-3 or cardiotro-
phin-like cytokine, and neuropoietin (NP) (reviewed in
Ref. 1). Because all members of this family use glycopro-
tein 130 (gp130) as a common signal transducer that is
required within their receptor complexes, the IL-6 family
members are referred to as the gp130 cytokines. The pri-
mary signal transduction pathway that mediates response
to gp130 cytokines is the Janus kinase/signal transducer
and activator of transcription (STAT) pathway, which pri-
marily activates STAT3.
The gp130 cytokines regulate a variety of biological
processes, including hematopoiesis, immune responses,
inflammation, stem cell potency, cardiovascular action,
and neuronal survival (reviewed in Ref. 2). Circulating
levels of many gp130 cytokines, namely IL-6, CT-1, LIF,
and OSM, have been observed in humans (3–9). Although
the actions of this cytokine family in white adipose tissue
(WAT) have not been fully elucidated, some gp130 cyto-
kines, including ciliary neurotrophic factor and IL-6, have
been targeted as potential therapeutic strategies in the
treatment of obesity (10). Some gp130 cytokines can exert
profound effects on WAT, body weight, and glucose and
lipid metabolism in rodents and humans (11–20). WAT
and its primary constituents, adipocytes, are highly re-
sponsive to gp130 cytokines (19, 21–25), but the effects of
these cytokines in adipose tissue have not been fully
elucidated.
An important function of adipose tissue includes the
production and secretion of factors (adipokines) that me-
diate whole-body metabolism. Several WAT-derived
factors have been investigated and shown to modulate
physiological systems as well as insulin resistance, inflam-
mation, and other pathological conditions (reviewed in
Ref. 26). WAT is a source of at least 2 gp130 cytokines,
IL-6 (27, 28) and CT-1 (7). In obesity, the expansion of
adipose tissue can be accompanied by a dysregulation of
adipocyte function and alterations in adipokine secretion
that can contribute to the development of metabolic dis-
eases (reviewed in Ref. 29). Obesity is often associated
with a state of chronic low-grade inflammation, mediated
in part by macrophage infiltration in adipose tissue (30),
and increased expression and secretion of proinflamma-
tory cytokines that contribute to insulin resistance and
type 2 diabetes mellitus (T2DM) (reviewed in Ref. 31). To
enhance our understanding of the potential role of cyto-
kines in the pathogenesis of obesity and related disorders,
we have focused on the expression and function of gp130
cytokines in adipose tissue.
OSM is a gp130 cytokine that shares substantial se-
quence identity with LIF (32, 33). Although originally
identified for its ability to inhibit cancer growth in humans
(34), OSM can modulate a variety of biological processes.
However, unlike other gp130 cytokines, OSM has its own
specific receptor that heterodimerizes with gp130 (35),
and this receptor, OSM receptor- (OSMR), mediates
most OSM effects. OSM can regulate inflammatory re-
sponses and is produced by activated T cells and macro-
phages (34, 36, 37). OSM can suppress inflammation in
murine models of chronic inflammatory disease such as
rheumatoid arthritis and multiple sclerosis (reviewed in
Ref. 38). Elevated OSM levels are found in inflammatory
diseases in humans, including rheumatoid arthritis and
atherosclerosis (39, 40). OSM can also regulate develop-
mental and regenerative processes in the liver (41–43).
Previous studies have shown that murine adipocytes in
vitro and WAT in vivo are responsive to OSM (44), and
importantly, this cytokine can inhibit preadipocyte differ-
entiation (25, 45). Cytokines that inhibit adipogenesis,
such as TNF and interferon-, tend to have metabolically
unfavorable effects such as the induction of insulin resis-
tance (reviewed in Ref. 46). One study suggests OSM can
attenuate adiponectin expression in human adipocytes
(47). Overall, the role of OSM in the pathogenesis of obe-
sity and related metabolic diseases is not understood. Nev-
ertheless, recent studies by Komori et al (48) suggest a
potential metabolically protective role for the OSM re-
ceptor, because mice with a global depletion of OSMR
exhibited obesity, insulin resistance, and adipose tissue
inflammation. However, our studies suggest that OSM
has negative effects on adipocytes.
Our results demonstrate for the first time that OSM
mRNA and protein levels are elevated in obese/T2DM
mice and humans. In addition, we observed a potential
relationship between OSM expression and body mass in-
dex (BMI) in human WAT. Interestingly, OSM is present
in nonadipocyte cells of human adipose tissue. In mice,
OSM is present in both Cd11c and Cd11c macrophages
that are F4/80 and found in adipose tissue of wild-type
and ob/ob mice. OSMR is highly expressed in adi-
pocytes, and its levels are increased in ob/ob mice and
high-fat diet (HFD)-fed mice compared with appropriate
controls. We also observed that OSM induces PAI-1 se-
cretion. In addition to body weight, increased OSM levels
correlate with insulin levels and have a negative associa-
tion with glucose disposal rates in a small human study.
Collectively, our data suggest that adipose tissue-derived
OSM may be a factor in metabolic disease states.
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DMEM was purchased from Sigma. Bovine and fetal bovine
sera were purchased from Hyclone. Mouse recombinant OSM,
CT-1, NP, and TNF and mouse PAI-1, OSM, and OSMR
antibodies were purchased from R&D Systems. Antibodies di-
rected against human OSM, STAT5A, peroxisome proliferator-
activated receptor-, F4/80, and the ERK antibodies were all
purchased from Santa Cruz Biotechnology. Mouse recombinant
LIF was purchased from BD Transduction. Adiponectin poly-
clonal antibody was from Affinity Bioreagents. Monocyte che-
moattractant protein-1 (MCP-1) rabbit polyclonal antibody was
from Cell Signaling. CT-1 antibody was from Calbiochem. Tri-
zol was from Invitrogen. Nitrocellulose was purchased from Bio-
Rad. The BCA kit and the enhanced chemiluminescence kit were
from Pierce. Horseradish peroxidase-conjugated secondary an-
tibodies were from Jackson ImmunoResearch Laboratories.
Mice
Animals used for this study included genetically obese male
B6.V-Lepob/J (B6-ob/ob) mice and their lean littermates as well
as C57BL/6J mice rendered obese by dietary intervention and
their lean controls. All mice were housed by the supplier (The
Jackson Laboratory) until shipment 1 to 2 weeks before tissue
harvest. B6-ob/ob mice and lean littermates were purchased for
experimentation at 6 weeks of age and given free access to stan-
dard laboratory chow. C57BL/6J mice subjected to diet-induced
obesity were fed an HFD consisting of 60% kcal from fat (Re-
search Diets Inc; D12492) from 6 weeks of age. Lean C57BL/6J
control mice were fed a control diet consisting of 10% kcal from
fat (Research Diet Inc; D12450B) from 6 weeks of age. Both diets
contained 10% kcal from protein with the balance in caloric
intake provided by differences in carbohydrate content. Mice
receiving both diets were given free access to food and shipped
for experimentation at 11 weeks of age. All animals were eutha-
nized by CO2 gas asphyxiation, and tissues were collected for
total RNA or whole-tissue extract isolation. Animal care and use
was approved by the Institutional Animal Care and Use Com-
mittee at Pennington Biomedical Research Center (PBRC). All
animal studies were conducted with 4 to 7 mice in each group.
Cell culture
Murine 3T3-L1 preadipocytes were grown to 2 days after
confluence in DMEM with 10% bovine serum. Medium was
changed every 48 hours. A cocktail containing 0.5 mmol/L
3-isobutyl-methylxanthine, 1 mol/L dexamethasone, and 1.7
mol/L insulin was used to induce preadipocytes differentiation
in DMEM containing 10% fetal bovine serum. After 48 hours,
the medium was replaced by DMEM with 10% fetal bovine
serum.
Human subjects and adipose tissue biopsies
All procedures and protocols were reviewed and approved by
PBRC or Indiana University Institutional Review Boards. Sub-
cutaneous adipose tissues were obtained with informed written
consent from healthy nondiabetic subjects undergoing elective
liposuction surgery. For fractionation, lipoaspirates were
washed in PBS, digested in PBS supplemented with 1% BSA,
0.1% collagenase type II (Worthington, Lakewood, NJ), and
2mM calcium chloride for 60 minutes with rocking at 37°C. The
tissue digest was centrifuged at 300g for 5 minutes at room tem-
perature to separate the floating mature adipocytes from the
stromovascular fraction (SVF) cell pellet. For RNA analysis, sc
adipose tissue was collected from the abdomen (5 cm to left/right
of the umbilicus) using a Bergstrom needle in compliance with
standard clinical practice at PBRC. Subjects undergoing bariatric
surgery had approximately 20 g of visceral adipose tissue ex-
tracted laparoscopically while under anesthesia.
RNA isolation from cells and tissue
RNA from 100 mg of tissue was isolated by column puri-
fication (QIAGEN) and yield determined by spectrophotometry
(NanoDrop Technologies). From each RNA sample, 200 ng was
reverse transcribed to cDNA using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems). Relative quan-
tification of mRNA expression was analyzed using ABI PRISM
7900 (Applied Biosystems). Mouse primers came from Inte-
grated DNA Technologies, and the sequences were as follows:
PAI-1 forward, CGGCACAACCCGACAGAGACA; PAI-1
reverse, TCCGAGGTCTGGGATGCTGGT; OSM forward,
AGGCACGGGCCAGAGTACCA; OSM reverse, GGCG-
GATATAGGGCTCCAAGAGTG; OSMR forward, CGTTC-
CCCTGTGAGGCCGAG; OSMR reverse, TCCTCCAA-
GACTTCGCTTCGGG; MCP1 forward, GCAGAGAGCCA
GACGGGAGGA; MCP1 reverse, TGGGGCGTTAACTG-
CATCTGG; IL6 forward, TCCTCTCTGCAAGAGACTTC-
CATCC; IL6 reverse, AAGCCTCCGACTTGTGAAGTGGT;
ADPN forward, AAAAGGGCTCAGGATGCTACTG; ADPN
reverse, TGGGCAGGATTAAGAGGAACA; PPIA (cyclo-
philin A) forward, CCACTGTCGCTTTTCGCCGC; PPIA (cy-
clophilin A) reverse, TGCAAACAGCTCGAAGGAGACGC;
and GAPDH forward, TTCCAGGAGCGAGACCCCAC;
GAPDH reverse, TTCAAGTGGGCCCCGGCCTT. For hu-
man RNA, custom TaqMan gene expression microfluidic cards
for OSM (Hs00968300_g1) were used. Samples were run in
triplicate, and expression levels were normalized to cyclophilin
B (Hs00168719_m1).
Adipose tissue macrophage isolation
SVF isolated from mouse adipose tissue samples were cooled
on ice, centrifuged at 500g for 5 minutes, and resuspended in
fluorescence-activated cell sorting (FACS) buffer at a concentra-
tion of 7  106 cells/mL. Cells were incubated in the dark at 4°C
on a bidirectional shaker for 30 minutes in FcBlock (20 g/mL)
(BD Pharmingen) and then for an additional 50 minutes with
fluorophore-conjugated primary antibodies or isotype control
antibodies. After incubation with primary antibodies, 1 mL
FACS buffer was added to the cells. Cells were centrifuged at
500g for 5 minutes and resuspended in 1 mL FACS buffer. The
wash was repeated twice. Cells were analyzed on a FACSCalibur
and analysis was performed using CellQuest software (Becton,
Dickinson and Co).
Gel electrophoresis and immunoblotting
Proteins were separated in 7.5% or 10% polyacrylamide gels
containing sodium dodecyl sulfate and transferred to nitrocel-
lulose membrane (Bio-Rad) in 25 mmol/L Tris, 192 mmol/L gly-
cine, and 20% methanol. After transfer, the membrane was
blocked in 4% milk for 1 hour at room temperature and incu-
bated with primary antibody overnight at 4°C. Results were
visualized with horseradish peroxidase-conjugated secondary
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antibodies (Jackson ImmunoResearch Laboratory) and en-
hanced chemiluminescence (Pierce).
Statistical analysis
Results are expressed as mean  SEM. Differences between
specified groups were analyzed using the Student’s t test (two-
tailed) for comparing 2 groups with P  .05 considered statis-
tically significant.
Results
Epididymal adipose tissue from 6-week-old ob/ and
ob/ob mice was used to isolate total RNA or to obtain
whole-tissue extracts for Western blot analysis. As shown
in Figure 1A, the levels of OSM and OSMR mRNA were
increased in adipose tissue from ob/ob mice compared
with lean littermates. We also observed a modest decrease
in CT-1 mRNA in the obese mice. As expected, we ob-
served statistically significant increases in IL-6,TNF, and
MCP-1 and a decline in adipsin mRNA in ob/ob mice. An
analysis of OSM protein levels revealed a notable increase
in adipose tissue from ob/ob mice compared with lean
littermates. The expression of STAT5A is shown as a pro-
tein loading control. Similar data were observed in epi-
didymal adipose tissue obtained from 18-week-old mice
fed a HFD for 12 weeks (Figure 1C). In this study,
C57BL/6J mice fed a HFD had significant increases in
OSM and OSMR mRNA levels compared with mice fed
a low-fat diet over the same period. There was no change
in LIF mRNA levels and a modest decline in CT-1 mRNA
levels. As expected, we observed statistically significant
increases in mRNA of IL-6, TNF, and MCP-1 and a
decline in adipsin mRNA in samples from the HFD mice.
Because we observed some nonspecific bands when per-
forming Western blot analysis on adipose tissue extracts
from the feeding study, we performed an immunoprecipi-
tation with an OSM antibody and examined the immu-
noprecipitated extract with a different OSM antibody. As
shown in both lighter and darker exposures in Figure 1D,
we observed a substantial increase in OSM protein levels
in HFD. Western blot analysis of these extracts also re-
vealed an expected increase in MCP-1 protein levels.
To determine whether the induction in OSM expres-
sion also occurred in human fat tissue in conditions of
obesity, we examined the expression of OSM protein from
subjects with BMIs ranging from 19.5 to 80.3. As shown
in Figure 2, there were very low levels of OSM protein in
BMIs ranging from 19.5 to 25.3. However, over a BMI
range of 40.8 to 80.3, there was a significant increase in the
Figure 1. OSM mRNA and protein levels are increased in adipose tissue of leptin-deficient mice and HFD-fed mice. A, Relative mRNA abundance
was assessed in epididymal fat pads of male 6-week-old lean (ob/) and leptin-deficient (ob/ob) mice. Data were normalized to 18S, and
differences between lean and obese animals were determined via Student’s t test where a P value of  .05 was considered significant. B, Whole-
tissue extracts were prepared from epididymal adipose tissue, and 100 g of protein was used for Western blot analysis to examine OSM protein
levels. C, Relative mRNA abundance was assessed in epididymal fat pads of male mice fed a low-fat diet (LFD) or HFD for 12 weeks. Data were
normalized to 18S, and differences between lean and obese animals were determined via Student’s t test where a P value of .05 was considered
significant. D, Whole-tissue extracts were prepared from epididymal adipose tissue, and 100 g of protein was used for Western blot analysis to
examine OSM protein levels. Abbreviations: IP, immunoprecipitation; WB, Western blot.
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expression of OSM protein. To follow up on these intrigu-
ing results, we examined OSM expression in adipose tissue
samples from morbidly obese individuals that were can-
didates for gastric bypass surgery. We had access only to
samples taken at the time of surgery. As shown in Figure
3A, we detected elevated OSM mRNA levels in omental
and mesenteric fat. We also observed an increase in OSM
mRNA levels from sc adipose tissue in the obese group
when compared with lean. Clinical data from these pa-
tients were used to search for potential correlations, and in
our limited study of 8 female patients, we observed that sc
OSM mRNA levels correlated with insulin levels (Figure
3C) and body weight (Figure 3D). The results in Figure 3B
also indicate OSM mRNA was inversely correlated with
glucose disposal rate. We did not observe any significant
correlations with OSMR expression and body weight,
insulin levels, or GDR in these subjects (data not shown).
Adipose tissue is composed of a variety of cell types, and
many cytokines produced in adipose tissue are made in
immune cells and not in adipocytes. We fractionated hu-
man adipose tissue from 2 obese subjects into adipocytes
and the other cells present, commonly referred to as the
SVF. As shown in Figure 4A, we observed that OSM was
primarily expressed in the SVF. In contrast, CT-1, another
gp130 cytokine, was expressed in both adipocytes and
SVF cells. Adiponectin was examined as a positive control
restricted solely to adipocyte expression, and STAT5A
was examined to demonstrate protein loading in both the
adipocytes and SVF cells. We also looked for the presence
of OSM in cultured adipocytes and were unable to detect
OSM secretion from adipocytes (Supplemental Figure 1,
published on The Endocrine Society’s Journals Online web-
site at http://jcem.endojournals.org). OSM is known to be
expressed in hematopoietic organs
and is found in various immune cell
types, including macrophages (49,
50). Hence, we examined the expres-
sion of OSM mRNA in adipose tis-
sue macrophages (ATMs) from 4 in-
dependent cohorts of male C57BL/6
lean and ob/ob mice at 14 weeks of
age. FBC represents ATMs that are
F4/80, CD11b, and CD11c. FB
represents ATMs that are F4/80,
CD11b, and CD11c. These re-
sults clearly demonstrate the expres-
sion of OSM in both types of ATMs.
Also, there was a modest decrease in
OSM mRNA in FBC compared with
FB in ob/ob mice (Figure 4B).
Because adipocytes are highly re-
sponsive to OSM and this cytokine is
known to primarily use the OSMR,
we examined the expression of this
highly specific OSM receptor over a
time course of adipocyte differentia-
tion in 3T3-L1 cells. As shown in
Supplemental Figure 2A, OSMR
mRNA and protein levels are nearly
equivalent in both preadipocytes and
mature adipocytes. The efficacy of
Figure 2. OSM levels are increased with higher BMI in sc human
adipose tissue. Frozen human adipose tissue samples were obtained
and used to prepare whole-tissue extracts. These were subjected to
Western blot analysis for human OSM. The expression of STAT5 was
examined to demonstrate equivalent protein loading for each sample.
The results were visualized with horseradish peroxidase-conjugated
secondary antibodies and chemiluminescence.
Figure 3. OSM mRNA in adipose tissue depots and correlations with body weight, insulin levels,
and glucose disposal rate (GDR) in humans. A, Different depots of human adipose tissue were
obtained before gastric bypass surgery, and RNA was extracted and processed for OSM mRNA
analysis. The results are expressed as mean values  SEM. Lowercase letters represent statistical
differences of P  .05. B–D, Subcutaneous adipose tissue from different patients was processed
for mRNA analysis. Euglycemic clamp was used for assessment of GDR in these patients. Glucose
disposal rate (milligrams per minute per kilogram) was calculated from the high dose of a 5-hour
2-step euglycemic (120 mg/dL), hyperinsulinemic (last 30 minutes of 2.5 hours of 400
mU/m2min insulin infusion after 2.5 hours at 50 mU/m2min). Body weight and blood insulin
levels were also measured. Abbreviations: AT, adipose tissue; AU, arbitrary units; Mesent,
mesenteric; Sub, sc; PPIA, cyclophilin A.
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adipogenesis is shown in Supplemental Figure 2B by ex-
amining peroxisome proliferator-activated receptor- ex-
pression. Of note, we did observe an increase in OSMR
levels during the clonal expansion of adipogenesis. We
also examined expression of OSMR in a variety of mu-
rine tissues. OSMR is highly expressed in brown and
white adipose tissue (Supplemental Figure 2C). These re-
sults clearly indicate that expression
of OSMR is present in adipocytes in
vitro and adipose tissue in vivo.
To date, few studies have focused
on the actions of OSM on adi-
pocytes. Because many cell types are
present in adipose tissue, we exam-
ined the effects of OSM on fully dif-
ferentiated murine 3T3-L1 adi-
pocytes. As shown in Figure 5, OSM
and TNF induce PAI-1 and IL-6
mRNA in adipocytes. However, the
effects of both of these cytokines re-
sults in an effect that is at least addi-
tive, suggesting these cytokines me-
diate their effect via independent
mechanisms. OSM also induces
MCP-1 mRNA levels in mature adi-
pocytes, but the induction is stronger
with TNF. TNF also inhibits adiponectin mRNA ex-
pression, but we did not observe any effects of OSM on
adiponectin levels in the presence or absence of TNF.
Next, we examined the effects of several gp130 cytokines
on the secretion of 2 known adipokines, MCP-1 and
PAI-1, from murine adipocytes. As shown in Figure 6A, all
of the gp130 cytokines examined
(CT-1, LIF, OSM, and NP) resulted
in an induction of MCP-1 secretion.
However, only OSM resulted in a ro-
bust increase in PAI-1 secretion. To
assess whether this response was di-
rectly regulated by OSM, we treated
mature adipocytes for 90 minutes
with various doses of OSM. Acute
OSM treatment resulted in a dose-
dependent increase in PAI-1 mRNA
levels (Figure 6B) and in the phos-
phorylation of OSMR, gp130, and
STAT3 (data not shown).
Discussion
Adipose tissue is highly sensitive to
several gp130 cytokines, including
OSM (44). Also, OSM inhibits adi-
pocyte differentiation in vitro (25,
45). In these studies, we observed
that OSM mRNA and protein levels
are increased in 2 rodent models of
obesity/T2DM. In human studies,
OSM protein was detectable in hu-
man adipose tissue and OSM expres-
Figure 4. OSM is present in nonadipocyte cells of human WAT. A, Human adipose tissue was
obtained and processed to separate adipocytes from the SVF as described in Materials and
Methods. From each sample 100 g was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. B, ATMs from 4 independent cohorts of male C57/BL6
lean and ob/ob mice at 14 weeks of age were isolated as indicated in Materials and Methods.
FBC represents ATMs that are F4/80, CD11b, and CD11c. FB represents ATMs that are F4/
80, CD11b, and CD11c.
Figure 5. OSM and TNF induce PAI-1, MCP-1, and IL-6 mRNA in murine adipocytes. Fully
differentiated 3T3-L1 adipocytes were treated with 1nM TNF, 1nM OSM, or both cytokines for
72 hours before harvesting. RNA was extracted and processed for PAI-1 (A), IL-6 (B), MCP-1 (C),
and ADPN (D) mRNA measurement. Each figure represents an experiment independently
performed 3 times. The results are expressed as mean values  SEM. Lowercase letters represent
statistical differences (P  .05).
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sion was elevated in WAT obtained from individuals with
BMI 40. We also analyzed fat tissue obtained from pa-
tients before gastric bypass surgery and observed that
OSM mRNA levels are higher in omental and mesenteric
fat when compared with sc fat tissue. In addition, in the
restricted number of samples we were able to analyze,
OSM levels in sc fat in women correlated with weight and
insulin levels and had an inverse correlation with glucose
disposal rates. Although this analysis was limited to 8 sub-
jects, theoverallmodulationofOSMinhuman fat samples
correlates with the increased expression of OSM mRNA
and protein levels we observed in both ob/ob and HFD
mice. Although further validation will be needed to iden-
tify human phenotypes associated with OSM expression,
our observations suggest that OSM levels are increased in
adipose tissue in conditions of obesity. Future investiga-
tions will be needed to determine whether OSM and its
receptor are affected by gender, race, and/or age.
Our in vitro studies in cultured 3T3-L1 adipocytes and
in vivo analyses in rodent and human adipose tissue sup-
port a working model whereby OSM is produced in adi-
pose tissue in conditions of excess adiposity. Our results
suggest that OSM is not produced by or secreted from
adipocytes but is expressed in 2 F4/80 populations of
macrophages that are CD11c and CD11c. Although we
observed a significant increase in OSM mRNA and pro-
tein in mouse and human adipose tissue with obesity, we
did not observe this same pattern of OSM mRNA regu-
lation in either population of F4/80 adipose tissue mac-
rophages (Figure 4B). These results suggest that OSM is
likely produced in additional nonadipocyte cells present in
adipose tissue, and further studies are necessary to identify
all of the cellular sources of OSM in adipose tissue. We
hypothesize that nonadipocyte-derived OSM acts in a
paracrine manner on adipocytes to promote metabolic
dysfunction. Our data showing that
OSM induces IL-6 and PAI-1 in a
manner similar to TNF support this
hypothesis. OSM also induces
MCP-1, but not to the same level as
TNF exposure. Although there is
some evidence that OSM can inhibit
adiponectin expression (47), we
were unable to observe this effect.
The discrepancy in our results and
the published study (47) can likely be
attributed to cells that were not fully
differentiated adipocytes. We and
others have shown that OSM inhib-
its adiponectin and other proteins
that are highly expressed during ad-
ipogenesis in vitro. Conversely, all of
our studies were performed in fully
differentiated mature adipocytes.
Our results also indicate that OSM is distinct from
other gp130 cytokines that use the Janus kinase/STAT
signaling pathway in adipocytes. As shown in Figure 6,
exposure to OSM, but not other gp130 cytokines, in-
creased secretion of PAI-1 from cultured adipocytes.
PAI-1 is known to be secreted from adipocytes and up-
regulated in conditions of obesity/T2DM (reviewed in
Ref. 51). Previous studies have also shown that PAI-1 ex-
pression is induced by OSM in human preadipocytes and
adipocytes isolated from sc and visceral adipose tissue (52)
and in human coronary artery and aortic cells (53). PAI-1
is also known to have profound effects on tissue fibrosis
(reviewed in Ref. 54). Elevated OSM in adipose tissue may
contribute to fibrosis, in part by modulation of PAI-1.
Overall, our observations suggest that nonadipocyte-de-
rived OSM acts in a paracrine manner on adipocytes to
promote the induction of IL-6, MCP-1, and PAI-1.
A very recent study examined the phenotype of mice
that lack the specific OSM receptor, OSMR. These stud-
ies showed that OSMR-null mice had mature-onset obe-
sity and insulin resistance (48). Moreover, administration
of OSM increased insulin sensitivity and polarized mac-
rophages to an M2 phenotype. The conclusion from these
studies was that OSM suppresses the development of in-
sulin resistance. This study contrasts with our current ob-
servations. One difference between our studies is that they
showed OSM mRNA was present at equivalent levels in
both the SVF and adipocyte fractions of adipose tissue.
Our studies failed to detect OSM in cultured murine adi-
pocytes, and fractionation of adipose tissue revealed that
most OSM protein was present in the SVF (Figure 4A). The
other study did not observe OSMR in adipocytes, al-
though we have substantial data documenting the pres-
Figure 6. OSM induces PAI-1 secretion from murine adipocytes. A, Fully differentiated 3T3-L1
adipocytes were treated with 1nM of the various cytokines indicated in the figure. CTL represents
untreated control cells. The mature adipocytes were treated daily, and after 96 hours, the
medium was collected and used for Western blot analysis. B, Fully differentiated 3T3-L1
adipocytes were treated with various doses of OSM for 90 minutes. RNA was extracted and
processed for PAI-1 and cyclophilin mRNA measurement. Each figure represents an experiment
independently performed 3 times. The ratio of PAI-1 to cyclophilin was calculated. Results are
expressed as mean  SEM. ****, P  .0001 between groups.
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ence of OSMR in mature adipocytes (Supplemental Fig-
ure 2B). Moreover, rodent adipose tissue in vivo is highly
responsive to OSM exposure (44), indicating that the
OSMR is present in adipocytes. We also observed an
increase in OSMR in the 2 rodent models of obesity we
examined (Figure 1), raising the possibility that adipocytes
might be more sensitive to OSM under these conditions.
Our model supports a role of OSM in inducing the ex-
pression of genes associated with inflammation and insu-
lin resistance. Therefore, we hypothesize that adipose tis-
sue-derived OSM promotes a metabolically unfavorable
phenotype. We predict that OSMR signaling in adi-
pocytes is likely involved in the pathogenesis of T2DM but
does not serve in a protective capacity as recently sug-
gested in mice that have a global knockout of the OSM
receptor (48). Studies in liver indicate that OSM, produced
in Kuppfer cells, can promote hepatic insulin resistance by
inhibiting insulin-induced Akt phosphorylation (55).
There is little question that many additional studies will be
necessary to identify all the adipose tissue sources of OSM
and to determine the overall function of this cytokine in
T2DM. Nonetheless, our results clearly demonstrate that
OSM levels are induced in murine and human obesity, and
OSM can modulate adipocyte gene expression in a manner
that is similar, but distinct, from TNF.
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